NASDAQ:CERS - Cerus Stock Price, Price Target & More

$5.66 +0.02 (+0.35 %)
(As of 04/19/2018 04:00 PM ET)
Previous Close$5.66
Today's Range$5.58 - $5.71
52-Week Range$1.93 - $5.85
Volume584,853 shs
Average Volume1.44 million shs
Market Capitalization$708.90 million
P/E Ratio-10.11
Dividend YieldN/A
Beta1.75

About Cerus (NASDAQ:CERS)

Cerus logoCerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company's INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.

Receive CERS News and Ratings via Email

Sign-up to receive the latest news and ratings for CERS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNASDAQ:CERS
CUSIP15708510
Phone925-288-6000

Debt

Debt-to-Equity Ratio0.77%
Current Ratio3.89%
Quick Ratio3.26%

Price-To-Earnings

Trailing P/E Ratio-10.11
Forward P/E Ratio-12.58
P/E GrowthN/A

Sales & Book Value

Annual Sales$43.57 million
Price / Sales16.84
Cash FlowN/A
Price / CashN/A
Book Value$0.34 per share
Price / Book16.65

Profitability

EPS (Most Recent Fiscal Year)($0.56)
Net Income$-60,580,000.00
Net Margins-139.06%
Return on Equity-154.46%
Return on Assets-66.63%

Miscellaneous

Employees215
Outstanding Shares129,600,000

How to Become a New Pot Stock Millionaire

Cerus (NASDAQ:CERS) Frequently Asked Questions

What is Cerus' stock symbol?

Cerus trades on the NASDAQ under the ticker symbol "CERS."

How were Cerus' earnings last quarter?

Cerus Co. (NASDAQ:CERS) released its quarterly earnings data on Thursday, March, 8th. The biotechnology company reported ($0.10) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.11) by $0.01. The biotechnology company had revenue of $16.20 million for the quarter, compared to the consensus estimate of $17.53 million. Cerus had a negative return on equity of 154.46% and a negative net margin of 139.06%. The company's quarterly revenue was up 60.4% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.13) earnings per share. View Cerus' Earnings History.

When is Cerus' next earnings date?

Cerus is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Cerus.

What price target have analysts set for CERS?

4 Wall Street analysts have issued 1 year target prices for Cerus' shares. Their predictions range from $5.00 to $6.00. On average, they expect Cerus' stock price to reach $5.25 in the next year. View Analyst Ratings for Cerus.

What are Wall Street analysts saying about Cerus stock?

Here are some recent quotes from research analysts about Cerus stock:
  • 1. According to Zacks Investment Research, "Cerus Corporation is developing medical products based on a platform technology that prevents nucleic acid replication. The company's initial application of this technology is the development of systems to inactivate viruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation. " (4/13/2018)
  • 2. Cantor Fitzgerald analysts commented, "This afternoon, CERS announced that its Ph 3 transfusion study (SPARC) evaluating its INTERCEPT-treated red blood cells in thalassemia (chronic anemia) patients achieved its primary efficacy and safety endpoints." (1/23/2018)

Who are some of Cerus' key competitors?

Who are Cerus' key executives?

Cerus' management team includes the folowing people:
  • Mr. William M. Greenman, Pres, CEO & Director (Age 51)
  • Dr. Laurence M. Corash M.D., Co-Founder, Chief Scientific Officer, Sr. VP & Corp. Director (Age 74)
  • Mr. Kevin D. Green, VP of Fin. & CFO (Age 46)
  • Dr. Richard J. Benjamin MBChB, Ph.D., Chief Medical Officer (Age 58)
  • Mr. Vivek K. Jayaraman, Chief Commercial Officer (Age 43)

Has Cerus been receiving favorable news coverage?

News coverage about CERS stock has been trending somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cerus earned a daily sentiment score of 0.12 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 47.74 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of Cerus?

Shares of CERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cerus' stock price today?

One share of CERS stock can currently be purchased for approximately $5.66.

How big of a company is Cerus?

Cerus has a market capitalization of $708.90 million and generates $43.57 million in revenue each year. The biotechnology company earns $-60,580,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Cerus employs 215 workers across the globe.

How can I contact Cerus?

Cerus' mailing address is 2550 STANWELL DRIVE, CONCORD CA, 94520. The biotechnology company can be reached via phone at 925-288-6000 or via email at [email protected]


MarketBeat Community Rating for Cerus (CERS)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  357 (Vote Outperform)
Underperform Votes:  186 (Vote Underperform)
Total Votes:  543
MarketBeat's community ratings are surveys of what our community members think about Cerus and other stocks. Vote "Outperform" if you believe CERS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CERS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cerus (NASDAQ:CERS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Cerus in the last 12 months. Their average twelve-month price target is $5.25, suggesting that the stock has a possible downside of 7.24%. The high price target for CERS is $6.00 and the low price target for CERS is $5.00. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.752.752.803.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.25$5.25$6.20$7.00
Price Target Upside: 7.24% downside7.80% upside61.46% upside131.79% upside

Cerus (NASDAQ:CERS) Consensus Price Target History

Price Target History for Cerus (NASDAQ:CERS)

Cerus (NASDAQ:CERS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/10/2018BTIG ResearchReiterated RatingHoldMediumView Rating Details
1/23/2018Cantor FitzgeraldReiterated RatingBuy$5.00HighView Rating Details
12/1/2017Robert W. BairdReiterated RatingBuy$5.00LowView Rating Details
10/5/2017CowenSet Price TargetBuy$6.00N/AView Rating Details
3/8/2017FBR & CoSet Price TargetBuy$10.00LowView Rating Details
(Data available from 4/19/2016 forward)

Earnings

Cerus (NASDAQ:CERS) Earnings History and Estimates Chart

Earnings by Quarter for Cerus (NASDAQ:CERS)

Cerus (NASDAQ:CERS) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.45 EPS
Next Year EPS Consensus Estimate: $-0.37 EPS

Cerus (NASDAQ CERS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018        
3/8/2018Q4 2017($0.11)($0.10)$17.53 million$16.20 millionViewListenView Earnings Details
11/2/2017Q3 2017($0.15)($0.12)$11.95 million$10.80 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.16)($0.16)$9.14 million$9.53 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.1650)($0.18)$8.98 million$7.01 millionViewListenView Earnings Details
3/7/2017Q4 2016($0.16)($0.13)$11.29 million$10.10 millionViewListenView Earnings Details
11/3/2016Q316($0.17)($0.14)$10.34 million$10.20 millionViewN/AView Earnings Details
8/4/2016Q216($0.17)($0.18)$8.88 million$9.25 millionViewN/AView Earnings Details
5/3/2016Q1($0.16)($0.17)$8.29 million$7.60 millionViewN/AView Earnings Details
3/8/2016Q415($0.16)($0.15)$9.72 million$9.70 millionViewListenView Earnings Details
11/5/2015Q315($0.16)($0.17)$10.00 million$8.04 millionViewN/AView Earnings Details
8/6/2015Q215($0.15)($0.17)$8.71 million$8.83 millionViewN/AView Earnings Details
5/5/2015Q214($0.16)($0.21)$7.70 million$7.70 millionViewN/AView Earnings Details
2/26/2015Q114($0.15)($0.25)$10.36 million$9.70 millionViewN/AView Earnings Details
11/4/2014Q413($0.13)($0.15)$9.83 million$10.36 millionViewN/AView Earnings Details
7/31/2014Q313($0.13)($0.16)$8.17 million$8.60 millionViewN/AView Earnings Details
5/1/2014Q313($0.09)($0.04)$9.65 million$7.86 millionViewN/AView Earnings Details
2/25/2014Q213($0.09)($0.10)$11.77 million$9.23 millionViewN/AView Earnings Details
10/29/2013($0.09)($0.29)$10.34 million$10.54 millionViewN/AView Earnings Details
7/30/2013Q2 2013($0.09)($0.10)$10.45 million$10.15 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.08)($0.11)$9.96 million$9.73 millionViewN/AView Earnings Details
2/28/2013Q4 2012($0.08)($0.11)ViewN/AView Earnings Details
11/7/2012Q3 2012($0.08)($0.10)ViewN/AView Earnings Details
8/2/2012Q2 2012($0.08)($0.17)ViewN/AView Earnings Details
5/1/2012Q1 2012($0.08)($0.08)ViewN/AView Earnings Details
2/28/2012Q4 2011($0.08)($0.09)ViewN/AView Earnings Details
11/1/2011Q3 2011($0.10)($0.06)ViewN/AView Earnings Details
7/28/2011Q2 2011($0.10)($0.13)ViewN/AView Earnings Details
4/28/2011Q1 2011($0.09)($0.11)ViewN/AView Earnings Details
3/3/2011Q4 2010($0.07)($0.05)ViewN/AView Earnings Details
10/28/2010Q3 2010($0.09)($0.10)ViewN/AView Earnings Details
7/29/2010Q2 2010($0.11)($0.14)ViewN/AView Earnings Details
4/29/2010Q1 2010($0.10)($0.13)ViewN/AView Earnings Details
2/23/2010Q4 2009($0.12)($0.13)ViewN/AView Earnings Details
10/29/2009Q3 2009($0.12)($0.16)ViewN/AView Earnings Details
7/30/2009Q2 2009($0.16)($0.19)ViewN/AView Earnings Details
4/30/2009Q1 2009($0.18)($0.21)ViewN/AView Earnings Details
2/26/2009Q4 2008($0.24)($0.20)ViewN/AView Earnings Details
10/30/2008Q3 2008($0.27)($0.27)ViewN/AView Earnings Details
7/31/2008Q2 2008($0.26)($0.28)ViewN/AView Earnings Details
5/1/2008Q1 2008($0.26)($0.16)ViewN/AView Earnings Details
2/21/2008Q4 2007($0.25)($0.32)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Cerus (NASDAQ:CERS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Cerus (NASDAQ CERS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.40%
Institutional Ownership Percentage: 51.93%
Insider Trading History for Cerus (NASDAQ:CERS)
Institutional Ownership by Quarter for Cerus (NASDAQ:CERS)

Cerus (NASDAQ CERS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/15/2018Laurence M CorashInsiderBuy150,011$5.15$772,556.651,462,580View SEC Filing  
3/13/2018Carol MooreSVPSell2,623$5.05$13,246.15View SEC Filing  
3/12/2018Chrystal MenardinsiderSell1,960$4.80$9,408.004,832View SEC Filing  
3/12/2018Kevin Dennis GreenCFOSell2,063$4.80$9,902.4058,062View SEC Filing  
3/12/2018William Mariner GreenmanCEOSell7,735$4.80$37,128.00View SEC Filing  
8/11/2017Laurence M CorashInsiderBuy92,796$2.45$227,350.201,375,711View SEC Filing  
3/15/2017Kevin Dennis GreenCFOSell2,343$4.21$9,864.03View SEC Filing  
3/15/2017William Mariner GreenmanInsiderSell8,786$4.21$36,989.06View SEC Filing  
3/14/2017Carol MooreSVPSell2,377$4.15$9,864.55View SEC Filing  
3/14/2017Richard J BenjaminInsiderSell1,189$4.15$4,934.353,000View SEC Filing  
8/22/2016Kevin Dennis GreenCFOSell17,150$6.80$116,620.00View SEC Filing  
8/19/2015Laurence M CorashInsiderBuy25,900$4.99$129,241.001,270,256View SEC Filing  
8/18/2015Laurence M CorashInsiderBuy84,600$4.77$403,542.00View SEC Filing  
11/10/2014William Mariner GreenmanCEOBuy21,800$3.93$85,674.00View SEC Filing  
11/19/2012William Mariner GreenmanCEOBuy3,200$3.02$9,664.00View SEC Filing  
11/16/2012Laurence M CorashInsiderBuy2,000$2.85$5,700.00View SEC Filing  
11/16/2012William Mariner GreenmanCEOBuy13,800$2.85$39,330.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Cerus (NASDAQ CERS) News Headlines

Source:
DateHeadline
Cerus (CERS) Lowered to "Hold" at Zacks Investment ResearchCerus (CERS) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 13 at 7:13 PM
Cerus (CERS) Lifted to "Hold" at BidaskClubCerus (CERS) Lifted to "Hold" at BidaskClub
www.americanbankingnews.com - April 12 at 6:47 PM
Zacks Investment Research Upgrades Cerus (CERS) to "Buy"Zacks Investment Research Upgrades Cerus (CERS) to "Buy"
www.americanbankingnews.com - April 10 at 1:42 PM
Cerus (CERS) Upgraded to Buy by Zacks Investment ResearchCerus (CERS) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - April 4 at 8:32 PM
Cerus Co. (CERS) Given Average Rating of "Buy" by AnalystsCerus Co. (CERS) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 4 at 9:32 AM
Cerus (CERS) Downgraded by Zacks Investment ResearchCerus (CERS) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 3 at 8:45 PM
BRIEF-Cerus Redes Phase 3 Red Blood Cell Study Expands Into The Continental USBRIEF-Cerus' Redes Phase 3 Red Blood Cell Study Expands Into The Continental US
www.reuters.com - April 2 at 8:57 AM
Cerus (CERS) Announces RedeS Phase 3 Red Blood Cell Study Expands Into Continental USCerus (CERS) Announces RedeS Phase 3 Red Blood Cell Study Expands Into Continental US
www.streetinsider.com - April 2 at 8:57 AM
Cerus RedeS Phase 3 Red Blood Cell Study Expands Into the Continental USCerus' RedeS Phase 3 Red Blood Cell Study Expands Into the Continental US
www.businesswire.com - April 2 at 8:57 AM
Cerus’ RedeS Phase 3 Red Blood Cell Study Expands Into the Continental U.S.Cerus’ RedeS Phase 3 Red Blood Cell Study Expands Into the Continental U.S.
finance.yahoo.com - April 2 at 8:57 AM
Blood transfusion company inks deal for new East Bay headquartersBlood transfusion company inks deal for new East Bay headquarters
finance.yahoo.com - March 28 at 5:09 PM
Cerus (CERS) Given Buy Rating at Cantor FitzgeraldCerus (CERS) Given Buy Rating at Cantor Fitzgerald
www.americanbankingnews.com - March 26 at 6:30 PM
Cerus (CERS) Stock Rating Upgraded by BidaskClubCerus (CERS) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - March 24 at 1:11 PM
Cerus Corporation, Shares Up 39% in the Past Month, Analysts Review, INTERCEPTCerus Corporation, Shares Up 39% in the Past Month, Analysts Review, INTERCEPT
finance.yahoo.com - March 22 at 8:42 AM
Cerus (CERS) Looks Good: Stock Adds 9.5% in Session - NasdaqCerus (CERS) Looks Good: Stock Adds 9.5% in Session - Nasdaq
www.nasdaq.com - March 20 at 8:44 AM
Cerus (CERS) Upgraded to "Strong-Buy" at BidaskClubCerus (CERS) Upgraded to "Strong-Buy" at BidaskClub
www.americanbankingnews.com - March 17 at 6:44 PM
Wired News – FDA Accepted Tyme’s IND Application to Begin Phase-II Clinical Study for SM-88 in Pancreatic CancerWired News – FDA Accepted Tyme’s IND Application to Begin Phase-II Clinical Study for SM-88 in Pancreatic Cancer
finance.yahoo.com - March 16 at 8:34 AM
Insider Buying: Cerus Co. (CERS) Insider Buys 150,011 Shares of StockInsider Buying: Cerus Co. (CERS) Insider Buys 150,011 Shares of Stock
www.americanbankingnews.com - March 15 at 7:46 PM
Is Cerus Corporation’s (NASDAQ:CERS) Balance Sheet A Threat To Its Future?Is Cerus Corporation’s (NASDAQ:CERS) Balance Sheet A Threat To Its Future?
finance.yahoo.com - March 15 at 8:30 AM
Cerus (CERS) Upgraded to "Hold" at ValuEngineCerus (CERS) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - March 15 at 12:28 AM
Cerus (CERS) Upgraded to "Hold" by Zacks Investment ResearchCerus (CERS) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - March 14 at 7:16 PM
Cerus Co. (CERS) SVP Sells $13,246.15 in StockCerus Co. (CERS) SVP Sells $13,246.15 in Stock
www.americanbankingnews.com - March 13 at 10:28 PM
Cerus Co. (CERS) CEO Sells $37,128.00 in StockCerus Co. (CERS) CEO Sells $37,128.00 in Stock
www.americanbankingnews.com - March 13 at 10:28 PM
Cerus Announces the Fourth Biologics License Application (BLA) Approval for a US Blood Center Customer - Business Wire (press release)Cerus Announces the Fourth Biologics License Application (BLA) Approval for a US Blood Center Customer - Business Wire (press release)
www.businesswire.com - March 13 at 8:41 AM
Cerus Announces the Fourth Biologics License Application (BLA) Approval for a U.S. Blood Center CustomerCerus Announces the Fourth Biologics License Application (BLA) Approval for a U.S. Blood Center Customer
finance.yahoo.com - March 13 at 8:41 AM
Cerus (CERS) Receives Hold Rating from BTIG ResearchCerus (CERS) Receives Hold Rating from BTIG Research
www.americanbankingnews.com - March 11 at 10:28 AM
Cerus Co. (CERS) Receives Average Recommendation of "Hold" from AnalystsCerus Co. (CERS) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - March 10 at 12:38 PM
Cerus (CERS) CEO Obi Greenman on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaCerus' (CERS) CEO Obi Greenman on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 9 at 8:38 AM
Cerus (CERS) Releases  Earnings Results, Beats Estimates By $0.01 EPSCerus (CERS) Releases Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - March 8 at 9:13 PM
Cerus Corporation to Host Earnings CallCerus Corporation to Host Earnings Call
finance.yahoo.com - March 8 at 6:22 PM
Cerus to Present at the Cowen and Company 38th Annual Health Care Conference on March 13, 2018Cerus to Present at the Cowen and Company 38th Annual Health Care Conference on March 13, 2018
finance.yahoo.com - March 7 at 8:37 AM
Millrace Asset Group Inc. Buys New Holdings in Cerus Co. (CERS)Millrace Asset Group Inc. Buys New Holdings in Cerus Co. (CERS)
www.americanbankingnews.com - March 5 at 12:54 PM
Cerus Co. (CERS) Short Interest Down 35.4% in FebruaryCerus Co. (CERS) Short Interest Down 35.4% in February
www.americanbankingnews.com - March 2 at 2:40 AM
-$0.12 Earnings Per Share Expected for Cerus Co. (CERS) This Quarter-$0.12 Earnings Per Share Expected for Cerus Co. (CERS) This Quarter
www.americanbankingnews.com - March 1 at 5:40 PM
Should You Be Holding Cerus Energy Group Ltd (CVE:CEA) Right Now?Should You Be Holding Cerus Energy Group Ltd (CVE:CEA) Right Now?
finance.yahoo.com - March 1 at 5:40 PM
Cerus (CERS) to Release Earnings on ThursdayCerus (CERS) to Release Earnings on Thursday
www.americanbankingnews.com - March 1 at 2:08 AM
Senvest Management LLC Has $10.70 Million Stake in Cerus Co. (CERS)Senvest Management LLC Has $10.70 Million Stake in Cerus Co. (CERS)
www.americanbankingnews.com - February 26 at 11:36 AM
ARK Investment Management LLC Boosts Holdings in Cerus Co. (CERS)ARK Investment Management LLC Boosts Holdings in Cerus Co. (CERS)
www.americanbankingnews.com - February 26 at 5:12 AM
Cerus to Release Fourth Quarter and Year End 2017 Results on March 8, 2018Cerus to Release Fourth Quarter and Year End 2017 Results on March 8, 2018
finance.yahoo.com - February 22 at 8:33 AM
Cerus (CERS) versus Obalon Therapeutics (OBLN) Head-To-Head ContrastCerus (CERS) versus Obalon Therapeutics (OBLN) Head-To-Head Contrast
www.americanbankingnews.com - February 14 at 5:06 AM
Cerus Co. (CERS) Given Average Recommendation of "Hold" by AnalystsCerus Co. (CERS) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - February 13 at 11:48 AM
 Analysts Expect Cerus Co. (CERS) to Announce -$0.12 Earnings Per Share Analysts Expect Cerus Co. (CERS) to Announce -$0.12 Earnings Per Share
www.americanbankingnews.com - February 12 at 11:10 PM
Contrasting Cerus (CERS) & Amedica (AMDA)Contrasting Cerus (CERS) & Amedica (AMDA)
www.americanbankingnews.com - February 6 at 9:14 AM
Cerus Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters Option to ... - Business Wire (press release)Cerus Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriter's Option to ... - Business Wire (press release)
www.businesswire.com - February 3 at 3:55 PM
Cerus Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriter’s Option to Purchase Additional SharesCerus Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriter’s Option to Purchase Additional Shares
finance.yahoo.com - February 3 at 9:37 AM
Cerus Announces Pricing of Public Offering of Common Stock - Business Wire (press release)Cerus Announces Pricing of Public Offering of Common Stock - Business Wire (press release)
www.businesswire.com - February 2 at 9:48 AM
Mid-Morning Market Update: Markets Open Higher; Boeing Beats Q4 EstimatesMid-Morning Market Update: Markets Open Higher; Boeing Beats Q4 Estimates
www.nasdaq.com - February 1 at 3:50 PM
Mid-Day Market Update: Cascadian Therapeutics Jumps Following Acquisition News; Bellicum Pharmaceuticals Shares PlungeMid-Day Market Update: Cascadian Therapeutics Jumps Following Acquisition News; Bellicum Pharmaceuticals Shares Plunge
www.nasdaq.com - January 31 at 3:51 PM
Cerus Announces Pricing of Public Offering of Common StockCerus Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - January 31 at 10:11 AM
Cerus Announces Public Offering of Common StockCerus Announces Public Offering of Common Stock
finance.yahoo.com - January 31 at 10:11 AM

SEC Filings

Cerus (NASDAQ:CERS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cerus (NASDAQ:CERS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cerus (NASDAQ CERS) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.